Skip to main content
. 2018 Aug 27;19(9):2541. doi: 10.3390/ijms19092541

Figure 3.

Figure 3

Survival and recurrence outcomes of patients with different expressions of P16INK4A, SOX2, and ALDH1A1 in tumors. (A,B) Cervical cancer patients with high P16INK4A expression had a better five-year OS rate (p = 0.016) and better five-year DFS rate (p = 0.02) than those with lower expression. (C,D) Patients with high SOX2 expression had similar five-year OS and DFS than those with low expression (C, p = 0.598 and D, p = 0.141). (E,F) Patients with high ALDH1A1 expression had similar five-year OS and DFS than those with low expression (E, p = 0.591 and F, p = 0.131). (G,H) The patients with low P16INK4A/high SOX2 expression had similar five-year OS rates (G, p = 0.118) but worse five-year DFS rates (H, p = 0.009) than those with high P16INK4A/lower SOX2 expression. (I,J) The patients with low P16INK4A/high ALDH1A1 expression had worse five-year OS rates (I, p = 0.030) and worse five-year DFS rates (J, p = 0.003) than those with high P16INK4A/lower ALDH1A1 expression.